Abselion has announced the opening of a US subsidiary at The Engine in Cambridge, Massachusetts.
The new location enhances the company's presence in the North American life sciences ecosystem, providing a formal base to support more direct engagement with academic, biotech and pharmaceutical research teams involved in biologics characterisation and development workflows.
According to Abselion, this new site in the US will provide it with an organisational framework to complement its established collaborations and support its next stage of development as interest in its Amperia protein quantification system extends beyond the UK and Europe.
The Engine, built by the Massachusetts Institute of Technology (MIT), is a Tough Tech incubator and accelerator and a strategic US hub for life sciences, biotech and other transformational technologies. It provides specialised infrastructure, deep technical collaboration and long-term company-building support.
Aligning Abselion's organisational structure with the geographic distribution of its customer base will enable the company to plan and coordinate its activities in North America more effectively.
This alignment will support Amperia system introductions, ongoing use and collaboration in the region, while Abselion continues to strengthen its scientific and operational foundations in the UK.
Additionally, expanding the company's global footprint will help establish the necessary structures to support future international growth.
Dr Ruizhi Wang, CEO and Founder, Abselion, said: "Our vision is to make high-quality quantification more accessible through closer international collaboration."
Establishing a US subsidiary marks an important milestone in Abselion's growth, strengthening our ability to operate across key life science markets globally while continuing to build on our strong scientific foundation.
"The US represents a significant focus for advanced biologics research and development."
"A formal presence there demonstrates our commitment to supporting long-term adoption of our protein quantification systems and will allow our growing international team to work more closely with customers and partners as they explore and build workflows around our Amperia platform."